Trial Profile
A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs Lufepirsen (Primary)
- Indications Wounds
- Focus Adverse reactions; Therapeutic Use
- Sponsors OcuNexus Therapeutics
- 08 Dec 2014 New trial record